General MedicationsORALStandard
MAXZIDE
HYDROCHLOROTHIAZIDE; TRIAMTERENE
Standard Dose
50MG;75MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview MAXZIDE is listed in Drugs@FDA under application 019129 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient HYDROCHLOROTHIAZIDE; TRIAMTERENE Form and strength TABLET;ORAL - 50MG;75MG Sponsor AUROBINDO PHARMA USA Submission history Latest submission status date: 2020-08-20 00:00:00.
Structured Monograph
Clinical summary
Approval overview MAXZIDE is listed in Drugs@FDA under application 019129 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient HYDROCHLOROTHIAZIDE; TRIAMTERENE Form and strength TABLET;ORAL - 50MG;75MG Sponsor AUROBINDO PHARMA USA Submission history Latest submission status date: 2020-08-20 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.